

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: C12N 15/70, 15/13, 15/62 C07K 15/28

A3 (42) I-10

(11) International Publication Number:

WO 93/22332

(43) International Publication Date:

11 November 1993 (11.11.93)

(21) International Application Number:

PCT/US93/03895

(22) International Filing Date:

26 April 1993 (26.04.93)

(30) Priority data:

07/873,930 07/963,333

24 April 1992 (24.04.92) U 19 October 1992 (19.10.92)

US (

(60) Parent Applications or Grants

(63) Related by Continuation US

Filed on US Filed on 07/963,333 (CIP) 19 October 1992 (19.10.92) 07/873,930 (CIP) 24 April 1992 (24.04.92)

(71) Applicant (for all designated States except US): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors; and

(75) Inventors/Applicants (for US only): WARD, Elizabeth, Sally [GB/US]; 12856 Noel Road, Apt. 2099, Dallas, TX 75230 (US). KIM, Jin-Kyoo [KR/US]; 4152 W. Pioneer Street, Apt. 1008, Irving, TX 75061 (US).

(74) Agent: KITCHELL, Barbara, S.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).


#### **Published**

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report: 17 February 1994 (17.02.94)

(54) Title: RECOMBINANT PRODUCTION OF IMMUNOGLOBULIN-LIKE DOMAINS IN PROKARYOTIC CELLS



### (57) Abstract

Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as T-cell variable domains, antidoby Fc-hinge fragments, subfragments and mutant domains with reduced biological half lives. Methods of producing large quantities of such domains, heterodimers, and fusion proteins following expression and secretion by prokaryotic host cells are also reported. Described are single chain T-cell receptors, which are folded into  $\beta$ -pleated sheet structures similar to those of immunoglobulin variable domains; antibody Fc and Fc-hinge domains, which have the same *in vivo* stability as intact antibodies; and domains engineered to have reduced *in vivo* half lives. These DNA constructs and protein domains will be useful as templates for *in vitro* mutagenesis and high resolution structural studies; for immunization and vaccination; and for the production of recombinant antibodies or chimaeric proteins with increased or decreased stability and longevity for therapeutic and diagnostic uses.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
ÂÜ	Australia	GA	Gabon	MW	Malawi
	Barbados	GB	United Kingdom	NE	Niger
BB		GN	Guinea	NL	Netherlands
BE	Belgium		Greece	NO	Norway
BF	Burkina Faso	GR		. NZ	New Zealand
BG	Bulgaria	ผบ	Hungary	PL	Poland
BJ	Benin	1E	Ireland	PT	Portugal
BR	Brazil	IT	ltaly		Romania
BY	Belarus	JP	Japan	RO	
	= = : : : :	KP	Democratic People's Republic	RU	Russian Federation
CA	Canada		of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo			SI	Slovenia
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'ivoire	u	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka		Chad
CN	China	·LU	Luxembourg	TD	
cs	Czechoslovakia	LV	Latvia	TG	Togo
		MC	Monaco	UA	Ukraine
CZ	Czech Republic	MG	Madagascar	US	United States of America
DE	Germany	ML	Mali	UZ	Uzbekistan
DK	Denmark			VN	Vict Nam
ES	Spain	MN	Mongolia	***	
PI	Finland				•



Inten nal Application No PCT/US 93/03895

		PCT/US 9	3/03895	
A. CLASS IPC 5	SIFICATION OF SUBJECT MATTER C12N15/70 C12N15/13 C12N15	/62 C07K15/28		
Ac∞rding	to international Patent Classification (IPC) or to both national cla	safication and IPC		
B. FIELD	S SEARCHED			
	documentation searched (classification system followed by classification s	ation symbols)	· · · · · · · · · · · · · · · · · · ·	
IPC 5	CO7K C12N			
Document	tion searched other than minimum documentation to the extent the	it such documents are included in the fields	searched	
Electronic	data base consulted during the international search (name of data b	ase and, where practical, search terms used)		
C DOCU	AFNITE CONFIDER ED TO DE RELEVANT		<del></del>	
	AENTS CONSIDERED TO BE RELEVANT	minmat - area - are	Butana Andria Na	
Category *	Citation of document, with indication, where appropriate, of the	renevant passages	Relevant to claim No.	
X	SCANDINAVIAN JOURNAL OF IMMUNOLO vol. 34, no. 2 , August 1991 pages 215 - 220	,	1-11,23, 25-31, 40,41	
	E.S. WARD 'Expression and secret T-cell receptor V-alpha and V-be using Escherichia coli as a host see abstract	ta domains		
:	see page 216, left column, parag see page 216, right column, last - page 218, right column, paragr	paragraph		
	***			
			,	
	*			
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed	in annex.	
'A' docum	tegories of cited documents :  ent defining the general state of the art which is not	T' later document published after the into or priority date and not in conflict wi cited to understand the principle or the	th the application but	
considered to be of particular relevance invention  "E" earlier document but published on or after the international filing date  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to				
which citatio	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	involve an inventive step when the do  'Y' document of particular relevance; the cannot be considered to involve an in document is combined with one or m	claimed invention ventive step when the	
	neans ant published prior to the international filing date but han the priority dats claimed	ments, such combination being obvior in the art.  "de" document member of the same patent	•	
	actual completion of the international search	Date of mailing of the international se		
2	3 November 1993	0 6 -01- 19	94	
Name and r	nailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer		
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	MONTERO LOPEZ, B		

Form PCT/ISA/210 (second sheet) (July 1992)

1



Inter: nal Application No
PCT/US 93/03895

(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/US 93/03895
tegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	NATURE vol. 341, no. 6242 , 12 October 1989 , LONDON GB pages 544 - 546 E. SALLY WARD ET AL. 'Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli' see abstract see page 544, right column, last paragraph - page 545, left column, paragraph 3	1-4,22, 25,26, 28-30,40
X	EP,A,O 368 684 (MEDICAL RESEARCH COUNCIL) 16 May 1990  see column 1, line 1 - line 10 see column 4, line 35 - column 5, line 32 see column 15, line 12 - line 25 see column 24, line 49 - column 26, line 30	1,3,4,8, 9,23,25, 26,28-30
X	WO,A,91 08298 (GENENTECH, INC.) 13 June 1991 see page 1, line 3 - line 6 see page 4, line 29 - page 5, line 2 see page 5, line 18 - line 23 see page 7, line 26 - line 36 see page 10, line 29 - line 38	44,45, 64-68
<b>(</b>	PATENT ABSTRACTS OF JAPAN vol. 13, no. 101 (C-574)(3449) 9 March 1989 & JP,A,63 276 496 (KYOWA HAKKO KOGYO CO LTD) 14 November 1988 see abstract	1,3-5, 12,23, 25,26, 28-30, 40,48
K	WO,A,92 01787 (CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED) 6 February 1992 see page 5, line 21 - line 28 see page 6, line 8 - page 8, line 21	64,65, 67,68
P,X	IMMUNOLOGY LETTERS vol. 33, no. 1 , June 1992 pages 53 - 60 MARK SUTER ET AL. 'Rabbit single domain antibodies specific to protein C expressed in prokaryotes' see page 53, right column, paragraph 2 - page 54, left column, paragraph 3 see page 54, right column, last paragraph - page 55, left column, paragraph 2	1,3,4, 25-30, 40,44,45

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

1



information on patent family members

Inter nal Application No PCT/US 93/03895

Patent document cited in search report	Publication date	Patent mem		Publication date
EP-A-0368684	16-05-90	AU-B- AU-A- WO-A- JP-T-	634186 4520189 9005144 3502801	18-02-93 28-05-90 17-05-90 27-06-91
WO-A-9108298	13-06-91	EP-A- JP-T-	052645 <i>2</i> 5503009	10-02-93 27-05-93
WO-A-9201787	06-02-92	AU-A- EP-A-	8238291 0540586	18-02-92 12-05-93

THIS PAGE BLANK (USPTO)